In the conventional world of academic research, disciplines operate in silos: biology departments focus on biology, engineering schools on engineering, and medical schools on patient care. But New York University’s Institute for Engineering Health is flipping this paradigm on its head. Instead of organizing expertise by field, the institute groups researchers around specific disease states. The driving question shifts from “what can engineers do for medicine?” to “what would it take to cure allergic asthma?”—and then assembles the necessary talent, whether immunologists, computational biologists, materials scientists, AI experts, or wireless communications engineers.
A New Organizing Principle for Research
Jeffrey Hubbell, vice president for bioengineering strategy and professor of chemical and biomolecular engineering at NYU Tandon School of Engineering, explains that the traditional model often leads to missed opportunities. “We’re used to putting a group of engineers in one building and medical researchers in another, hoping they’ll collaborate,” he says. “But by anchoring the institute around diseases, we force experts from different backgrounds to work together from the start.” This disease-centric structure has already yielded tangible results.
Early Successes: From Devices to Therapies
One notable collaboration combined a chemical engineer and an electrical engineer to develop a device that detects airborne threats—including disease pathogens. That innovation has now spun off into a startup company. Another project brought a visually impaired physician together with mechanical engineers to create navigation technology that helps blind subway riders travel independently. And Hubbell’s own research on “inverse vaccines” aims to reprogram the immune system to treat conditions such as celiac disease and allergies—work that requires fluent interplay between immunology, molecular engineering, and materials science.
The Conceptual Shift: From Inhibition to Activation
Underlying these collaborations is a fundamental rethinking of therapeutic strategy. Modern medicine has largely optimized around blocking harmful molecules or suppressing immune responses. Antibody technology, for instance, is superb at inhibiting one specific target at a time. “It’s really fit for purpose for blocking one thing at a time,” notes Hubbell. The pharmaceutical industry has become extraordinarily adept at creating such inhibitors, each designed to shut down a single pathway.
But Hubbell poses a provocative alternative: What if we could promote one beneficial process that sets off a cascade to counteract multiple harmful pathways simultaneously? In inflammation, instead of blocking inflammatory molecules one by one, could the immune system be nudged toward tolerance? In cancer, could a single intervention drive pro-inflammatory signals within the tumor microenvironment that overcome several immune-suppressive features at once?
A New Toolkit for Activation
Moving from inhibition to activation requires a different set of tools—and a different kind of researcher. “We’re using biological molecules like proteins, or material-based structures like soluble polymers and supramolecular nanomaterials, to drive these more fundamental features,” says Hubbell. This approach leverages the body’s own regulatory networks to create robust, multi-target effects, rather than relying on a constant stream of single-target drugs.
Why This Matters for the Future of Health Research
NYU’s model is still young, but early evidence suggests it can accelerate the translation of basic science into real-world solutions. By organizing around diseases, researchers naturally cross disciplinary boundaries—and that is precisely where breakthroughs often emerge. The institute’s focus on activation, rather than mere inhibition, also opens up entirely new categories of therapies.
For medical research to keep pace with complex diseases, we may need more such disease-first models that prioritize problems over departments. As Hubbell’s work on inverse vaccines and the ongoing collaborations show, when engineers, biologists, clinicians, and materials scientists share a common challenge, the result can be far greater than the sum of their parts.